Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020 Initiated patient enrollment in ASCEND™ Phase 3 open-label safety trial of …